CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

•MF hematopoietic stem cells aberrantly secrete CXCL8 and exhibit enhanced cell growth/output in response to CXCL8 in vitro.•Genetic deletion or inhibition of Cxcr2 in the hMPLW515L-adoptive transfer model ameliorates fibrosis and improves hematologic parameters. [Display omitted] Proinflammatory si...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2023-05, Vol.141 (20), p.2508-2519
Hauptverfasser: Dunbar, Andrew J., Kim, Dongjoo, Lu, Min, Farina, Mirko, Bowman, Robert L., Yang, Julie L., Park, Young, Karzai, Abdul, Xiao, Wenbin, Zaroogian, Zach, O’Connor, Kavi, Mowla, Shoron, Gobbo, Francesca, Verachi, Paola, Martelli, Fabrizio, Sarli, Giuseppe, Xia, Lijuan, Elmansy, Nada, Kleppe, Maria, Chen, Zhuo, Xiao, Yang, McGovern, Erin, Snyder, Jenna, Krishnan, Aishwarya, Hill, Corrine, Cordner, Keith, Zouak, Anouar, Salama, Mohamed E., Yohai, Jayden, Tucker, Eric, Chen, Jonathan, Zhou, Jing, McConnell, Timothy, Migliaccio, Anna R., Koche, Richard, Rampal, Raajit, Fan, Rong, Levine, Ross L., Hoffman, Ronald
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2519
container_issue 20
container_start_page 2508
container_title Blood
container_volume 141
creator Dunbar, Andrew J.
Kim, Dongjoo
Lu, Min
Farina, Mirko
Bowman, Robert L.
Yang, Julie L.
Park, Young
Karzai, Abdul
Xiao, Wenbin
Zaroogian, Zach
O’Connor, Kavi
Mowla, Shoron
Gobbo, Francesca
Verachi, Paola
Martelli, Fabrizio
Sarli, Giuseppe
Xia, Lijuan
Elmansy, Nada
Kleppe, Maria
Chen, Zhuo
Xiao, Yang
McGovern, Erin
Snyder, Jenna
Krishnan, Aishwarya
Hill, Corrine
Cordner, Keith
Zouak, Anouar
Salama, Mohamed E.
Yohai, Jayden
Tucker, Eric
Chen, Jonathan
Zhou, Jing
McConnell, Timothy
Migliaccio, Anna R.
Koche, Richard
Rampal, Raajit
Fan, Rong
Levine, Ross L.
Hoffman, Ronald
description •MF hematopoietic stem cells aberrantly secrete CXCL8 and exhibit enhanced cell growth/output in response to CXCL8 in vitro.•Genetic deletion or inhibition of Cxcr2 in the hMPLW515L-adoptive transfer model ameliorates fibrosis and improves hematologic parameters. [Display omitted] Proinflammatory signaling is a hallmark feature of human cancer, including in myeloproliferative neoplasms (MPNs), most notably myelofibrosis (MF). Dysregulated inflammatory signaling contributes to fibrotic progression in MF; however, the individual cytokine mediators elicited by malignant MPN cells to promote collagen-producing fibrosis and disease evolution are yet to be fully elucidated. Previously, we identified a critical role for combined constitutive JAK/STAT and aberrant NF-κB proinflammatory signaling in MF development. Using single-cell transcriptional and cytokine-secretion studies of primary cells from patients with MF and the human MPLW515L (hMPLW515L) murine model of MF, we extend our previous work and delineate the role of CXCL8/CXCR2 signaling in MF pathogenesis and bone marrow fibrosis progression. Hematopoietic stem/progenitor cells from patients with MF are enriched for a CXCL8/CXCR2 gene signature and display enhanced proliferation and fitness in response to an exogenous CXCL8 ligand in vitro. Genetic deletion of Cxcr2 in the hMPLW515L-adoptive transfer model abrogates fibrosis and extends overall survival, and pharmacologic inhibition of the CXCR1/2 pathway improves hematologic parameters, attenuates bone marrow fibrosis, and synergizes with JAK inhibitor therapy. Our mechanistic insights provide a rationale for therapeutic targeting of the CXCL8/CXCR2 pathway among patients with MF. Cytokines are known to be proinflammatory messengers in myeloproliferative neoplasms (MPNs) and are suspected to be important in the late stages of these diseases. Using primary human samples, single-cell cytokine profiling, and murine models, Dunbar and colleagues reveal that the CXCL8/CXCR2 cytokine-signaling axis is a key mediator of bone marrow fibrosis in MPN, providing a therapeutically tractable avenue to prevent, or treat, this lethal complication of MPN
doi_str_mv 10.1182/blood.2022015418
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10273167</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497123004329</els_id><sourcerecordid>2815249369</sourcerecordid><originalsourceid>FETCH-LOGICAL-e318t-6e5694c06b99ac96bc152a2a542f91eeba11a490bef1ec188822c4e8a0a800303</originalsourceid><addsrcrecordid>eNpVUU1PGzEQtVARBNp7T5WPvSyMvbuO3UtVRXxJkZAQlXpzZ51JcLWxU9sB8e8xBQpcZg7z9D7mMfZZwJEQWh4PY4yLIwlSgug7oXfYRPRSNwASPrAJAKimM1Oxzw5y_gMgulb2e2y_VRqgV9MJ-z37NZvr4zqvJM9-FXD0YcXXtPBYKPMhBuJrTCne8aUfUsw-cwwL_rh4uaGEG9oW73jBtKLCfeDrexrjC_gj213imOnT8z5kP09Prmfnzfzy7GL2Y95QK3RpFPXKdA7UYAw6owZXg6DEvpNLI4gGFAI7AwMtBTmhtZbSdaQRsEZpoT1k3594N9uhuncUSsLRbpKv7u9tRG_fX4K_sat4awXIaSvUtDJ8fWZI8e-WcrFrnx2NIwaK22ylrpY60ypToV_eiv1XeflrBXx7AlCNfOsp2ew8BVffmsgVu4i-CtvHEu2_Eu1rie0DE2iPgQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2815249369</pqid></control><display><type>article</type><title>CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Dunbar, Andrew J. ; Kim, Dongjoo ; Lu, Min ; Farina, Mirko ; Bowman, Robert L. ; Yang, Julie L. ; Park, Young ; Karzai, Abdul ; Xiao, Wenbin ; Zaroogian, Zach ; O’Connor, Kavi ; Mowla, Shoron ; Gobbo, Francesca ; Verachi, Paola ; Martelli, Fabrizio ; Sarli, Giuseppe ; Xia, Lijuan ; Elmansy, Nada ; Kleppe, Maria ; Chen, Zhuo ; Xiao, Yang ; McGovern, Erin ; Snyder, Jenna ; Krishnan, Aishwarya ; Hill, Corrine ; Cordner, Keith ; Zouak, Anouar ; Salama, Mohamed E. ; Yohai, Jayden ; Tucker, Eric ; Chen, Jonathan ; Zhou, Jing ; McConnell, Timothy ; Migliaccio, Anna R. ; Koche, Richard ; Rampal, Raajit ; Fan, Rong ; Levine, Ross L. ; Hoffman, Ronald</creator><creatorcontrib>Dunbar, Andrew J. ; Kim, Dongjoo ; Lu, Min ; Farina, Mirko ; Bowman, Robert L. ; Yang, Julie L. ; Park, Young ; Karzai, Abdul ; Xiao, Wenbin ; Zaroogian, Zach ; O’Connor, Kavi ; Mowla, Shoron ; Gobbo, Francesca ; Verachi, Paola ; Martelli, Fabrizio ; Sarli, Giuseppe ; Xia, Lijuan ; Elmansy, Nada ; Kleppe, Maria ; Chen, Zhuo ; Xiao, Yang ; McGovern, Erin ; Snyder, Jenna ; Krishnan, Aishwarya ; Hill, Corrine ; Cordner, Keith ; Zouak, Anouar ; Salama, Mohamed E. ; Yohai, Jayden ; Tucker, Eric ; Chen, Jonathan ; Zhou, Jing ; McConnell, Timothy ; Migliaccio, Anna R. ; Koche, Richard ; Rampal, Raajit ; Fan, Rong ; Levine, Ross L. ; Hoffman, Ronald</creatorcontrib><description>•MF hematopoietic stem cells aberrantly secrete CXCL8 and exhibit enhanced cell growth/output in response to CXCL8 in vitro.•Genetic deletion or inhibition of Cxcr2 in the hMPLW515L-adoptive transfer model ameliorates fibrosis and improves hematologic parameters. [Display omitted] Proinflammatory signaling is a hallmark feature of human cancer, including in myeloproliferative neoplasms (MPNs), most notably myelofibrosis (MF). Dysregulated inflammatory signaling contributes to fibrotic progression in MF; however, the individual cytokine mediators elicited by malignant MPN cells to promote collagen-producing fibrosis and disease evolution are yet to be fully elucidated. Previously, we identified a critical role for combined constitutive JAK/STAT and aberrant NF-κB proinflammatory signaling in MF development. Using single-cell transcriptional and cytokine-secretion studies of primary cells from patients with MF and the human MPLW515L (hMPLW515L) murine model of MF, we extend our previous work and delineate the role of CXCL8/CXCR2 signaling in MF pathogenesis and bone marrow fibrosis progression. Hematopoietic stem/progenitor cells from patients with MF are enriched for a CXCL8/CXCR2 gene signature and display enhanced proliferation and fitness in response to an exogenous CXCL8 ligand in vitro. Genetic deletion of Cxcr2 in the hMPLW515L-adoptive transfer model abrogates fibrosis and extends overall survival, and pharmacologic inhibition of the CXCR1/2 pathway improves hematologic parameters, attenuates bone marrow fibrosis, and synergizes with JAK inhibitor therapy. Our mechanistic insights provide a rationale for therapeutic targeting of the CXCL8/CXCR2 pathway among patients with MF. Cytokines are known to be proinflammatory messengers in myeloproliferative neoplasms (MPNs) and are suspected to be important in the late stages of these diseases. Using primary human samples, single-cell cytokine profiling, and murine models, Dunbar and colleagues reveal that the CXCL8/CXCR2 cytokine-signaling axis is a key mediator of bone marrow fibrosis in MPN, providing a therapeutically tractable avenue to prevent, or treat, this lethal complication of MPN</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.2022015418</identifier><identifier>PMID: 36800567</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Cytokines - metabolism ; Humans ; Janus Kinase 2 - genetics ; Janus Kinase 2 - metabolism ; Mice ; Myeloid Neoplasia ; Myeloproliferative Disorders - genetics ; Neoplasms - complications ; Primary Myelofibrosis - pathology ; Signal Transduction</subject><ispartof>Blood, 2023-05, Vol.141 (20), p.2508-2519</ispartof><rights>2023 The American Society of Hematology</rights><rights>2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.</rights><rights>2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2023 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-2980-9028 ; 0000-0002-8294-8748 ; 0000-0003-4747-6391 ; 0000-0001-7805-8059 ; 0000-0003-3777-5961 ; 0000-0001-8586-8500 ; 0000-0002-7949-0609 ; 0000-0002-5628-5442 ; 0000-0002-7811-242X ; 0000-0001-7567-0066 ; 0000-0001-6405-3484 ; 0000-0001-7878-4923 ; 0000-0002-4082-4675 ; 0000-0001-6191-5966 ; 0000-0003-1800-271X ; 0000-0002-8231-8420</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,782,786,887,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36800567$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dunbar, Andrew J.</creatorcontrib><creatorcontrib>Kim, Dongjoo</creatorcontrib><creatorcontrib>Lu, Min</creatorcontrib><creatorcontrib>Farina, Mirko</creatorcontrib><creatorcontrib>Bowman, Robert L.</creatorcontrib><creatorcontrib>Yang, Julie L.</creatorcontrib><creatorcontrib>Park, Young</creatorcontrib><creatorcontrib>Karzai, Abdul</creatorcontrib><creatorcontrib>Xiao, Wenbin</creatorcontrib><creatorcontrib>Zaroogian, Zach</creatorcontrib><creatorcontrib>O’Connor, Kavi</creatorcontrib><creatorcontrib>Mowla, Shoron</creatorcontrib><creatorcontrib>Gobbo, Francesca</creatorcontrib><creatorcontrib>Verachi, Paola</creatorcontrib><creatorcontrib>Martelli, Fabrizio</creatorcontrib><creatorcontrib>Sarli, Giuseppe</creatorcontrib><creatorcontrib>Xia, Lijuan</creatorcontrib><creatorcontrib>Elmansy, Nada</creatorcontrib><creatorcontrib>Kleppe, Maria</creatorcontrib><creatorcontrib>Chen, Zhuo</creatorcontrib><creatorcontrib>Xiao, Yang</creatorcontrib><creatorcontrib>McGovern, Erin</creatorcontrib><creatorcontrib>Snyder, Jenna</creatorcontrib><creatorcontrib>Krishnan, Aishwarya</creatorcontrib><creatorcontrib>Hill, Corrine</creatorcontrib><creatorcontrib>Cordner, Keith</creatorcontrib><creatorcontrib>Zouak, Anouar</creatorcontrib><creatorcontrib>Salama, Mohamed E.</creatorcontrib><creatorcontrib>Yohai, Jayden</creatorcontrib><creatorcontrib>Tucker, Eric</creatorcontrib><creatorcontrib>Chen, Jonathan</creatorcontrib><creatorcontrib>Zhou, Jing</creatorcontrib><creatorcontrib>McConnell, Timothy</creatorcontrib><creatorcontrib>Migliaccio, Anna R.</creatorcontrib><creatorcontrib>Koche, Richard</creatorcontrib><creatorcontrib>Rampal, Raajit</creatorcontrib><creatorcontrib>Fan, Rong</creatorcontrib><creatorcontrib>Levine, Ross L.</creatorcontrib><creatorcontrib>Hoffman, Ronald</creatorcontrib><title>CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis</title><title>Blood</title><addtitle>Blood</addtitle><description>•MF hematopoietic stem cells aberrantly secrete CXCL8 and exhibit enhanced cell growth/output in response to CXCL8 in vitro.•Genetic deletion or inhibition of Cxcr2 in the hMPLW515L-adoptive transfer model ameliorates fibrosis and improves hematologic parameters. [Display omitted] Proinflammatory signaling is a hallmark feature of human cancer, including in myeloproliferative neoplasms (MPNs), most notably myelofibrosis (MF). Dysregulated inflammatory signaling contributes to fibrotic progression in MF; however, the individual cytokine mediators elicited by malignant MPN cells to promote collagen-producing fibrosis and disease evolution are yet to be fully elucidated. Previously, we identified a critical role for combined constitutive JAK/STAT and aberrant NF-κB proinflammatory signaling in MF development. Using single-cell transcriptional and cytokine-secretion studies of primary cells from patients with MF and the human MPLW515L (hMPLW515L) murine model of MF, we extend our previous work and delineate the role of CXCL8/CXCR2 signaling in MF pathogenesis and bone marrow fibrosis progression. Hematopoietic stem/progenitor cells from patients with MF are enriched for a CXCL8/CXCR2 gene signature and display enhanced proliferation and fitness in response to an exogenous CXCL8 ligand in vitro. Genetic deletion of Cxcr2 in the hMPLW515L-adoptive transfer model abrogates fibrosis and extends overall survival, and pharmacologic inhibition of the CXCR1/2 pathway improves hematologic parameters, attenuates bone marrow fibrosis, and synergizes with JAK inhibitor therapy. Our mechanistic insights provide a rationale for therapeutic targeting of the CXCL8/CXCR2 pathway among patients with MF. Cytokines are known to be proinflammatory messengers in myeloproliferative neoplasms (MPNs) and are suspected to be important in the late stages of these diseases. Using primary human samples, single-cell cytokine profiling, and murine models, Dunbar and colleagues reveal that the CXCL8/CXCR2 cytokine-signaling axis is a key mediator of bone marrow fibrosis in MPN, providing a therapeutically tractable avenue to prevent, or treat, this lethal complication of MPN</description><subject>Animals</subject><subject>Cytokines - metabolism</subject><subject>Humans</subject><subject>Janus Kinase 2 - genetics</subject><subject>Janus Kinase 2 - metabolism</subject><subject>Mice</subject><subject>Myeloid Neoplasia</subject><subject>Myeloproliferative Disorders - genetics</subject><subject>Neoplasms - complications</subject><subject>Primary Myelofibrosis - pathology</subject><subject>Signal Transduction</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUU1PGzEQtVARBNp7T5WPvSyMvbuO3UtVRXxJkZAQlXpzZ51JcLWxU9sB8e8xBQpcZg7z9D7mMfZZwJEQWh4PY4yLIwlSgug7oXfYRPRSNwASPrAJAKimM1Oxzw5y_gMgulb2e2y_VRqgV9MJ-z37NZvr4zqvJM9-FXD0YcXXtPBYKPMhBuJrTCne8aUfUsw-cwwL_rh4uaGEG9oW73jBtKLCfeDrexrjC_gj213imOnT8z5kP09Prmfnzfzy7GL2Y95QK3RpFPXKdA7UYAw6owZXg6DEvpNLI4gGFAI7AwMtBTmhtZbSdaQRsEZpoT1k3594N9uhuncUSsLRbpKv7u9tRG_fX4K_sat4awXIaSvUtDJ8fWZI8e-WcrFrnx2NIwaK22ylrpY60ypToV_eiv1XeflrBXx7AlCNfOsp2ew8BVffmsgVu4i-CtvHEu2_Eu1rie0DE2iPgQ</recordid><startdate>20230518</startdate><enddate>20230518</enddate><creator>Dunbar, Andrew J.</creator><creator>Kim, Dongjoo</creator><creator>Lu, Min</creator><creator>Farina, Mirko</creator><creator>Bowman, Robert L.</creator><creator>Yang, Julie L.</creator><creator>Park, Young</creator><creator>Karzai, Abdul</creator><creator>Xiao, Wenbin</creator><creator>Zaroogian, Zach</creator><creator>O’Connor, Kavi</creator><creator>Mowla, Shoron</creator><creator>Gobbo, Francesca</creator><creator>Verachi, Paola</creator><creator>Martelli, Fabrizio</creator><creator>Sarli, Giuseppe</creator><creator>Xia, Lijuan</creator><creator>Elmansy, Nada</creator><creator>Kleppe, Maria</creator><creator>Chen, Zhuo</creator><creator>Xiao, Yang</creator><creator>McGovern, Erin</creator><creator>Snyder, Jenna</creator><creator>Krishnan, Aishwarya</creator><creator>Hill, Corrine</creator><creator>Cordner, Keith</creator><creator>Zouak, Anouar</creator><creator>Salama, Mohamed E.</creator><creator>Yohai, Jayden</creator><creator>Tucker, Eric</creator><creator>Chen, Jonathan</creator><creator>Zhou, Jing</creator><creator>McConnell, Timothy</creator><creator>Migliaccio, Anna R.</creator><creator>Koche, Richard</creator><creator>Rampal, Raajit</creator><creator>Fan, Rong</creator><creator>Levine, Ross L.</creator><creator>Hoffman, Ronald</creator><general>Elsevier Inc</general><general>The American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2980-9028</orcidid><orcidid>https://orcid.org/0000-0002-8294-8748</orcidid><orcidid>https://orcid.org/0000-0003-4747-6391</orcidid><orcidid>https://orcid.org/0000-0001-7805-8059</orcidid><orcidid>https://orcid.org/0000-0003-3777-5961</orcidid><orcidid>https://orcid.org/0000-0001-8586-8500</orcidid><orcidid>https://orcid.org/0000-0002-7949-0609</orcidid><orcidid>https://orcid.org/0000-0002-5628-5442</orcidid><orcidid>https://orcid.org/0000-0002-7811-242X</orcidid><orcidid>https://orcid.org/0000-0001-7567-0066</orcidid><orcidid>https://orcid.org/0000-0001-6405-3484</orcidid><orcidid>https://orcid.org/0000-0001-7878-4923</orcidid><orcidid>https://orcid.org/0000-0002-4082-4675</orcidid><orcidid>https://orcid.org/0000-0001-6191-5966</orcidid><orcidid>https://orcid.org/0000-0003-1800-271X</orcidid><orcidid>https://orcid.org/0000-0002-8231-8420</orcidid></search><sort><creationdate>20230518</creationdate><title>CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis</title><author>Dunbar, Andrew J. ; Kim, Dongjoo ; Lu, Min ; Farina, Mirko ; Bowman, Robert L. ; Yang, Julie L. ; Park, Young ; Karzai, Abdul ; Xiao, Wenbin ; Zaroogian, Zach ; O’Connor, Kavi ; Mowla, Shoron ; Gobbo, Francesca ; Verachi, Paola ; Martelli, Fabrizio ; Sarli, Giuseppe ; Xia, Lijuan ; Elmansy, Nada ; Kleppe, Maria ; Chen, Zhuo ; Xiao, Yang ; McGovern, Erin ; Snyder, Jenna ; Krishnan, Aishwarya ; Hill, Corrine ; Cordner, Keith ; Zouak, Anouar ; Salama, Mohamed E. ; Yohai, Jayden ; Tucker, Eric ; Chen, Jonathan ; Zhou, Jing ; McConnell, Timothy ; Migliaccio, Anna R. ; Koche, Richard ; Rampal, Raajit ; Fan, Rong ; Levine, Ross L. ; Hoffman, Ronald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e318t-6e5694c06b99ac96bc152a2a542f91eeba11a490bef1ec188822c4e8a0a800303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Cytokines - metabolism</topic><topic>Humans</topic><topic>Janus Kinase 2 - genetics</topic><topic>Janus Kinase 2 - metabolism</topic><topic>Mice</topic><topic>Myeloid Neoplasia</topic><topic>Myeloproliferative Disorders - genetics</topic><topic>Neoplasms - complications</topic><topic>Primary Myelofibrosis - pathology</topic><topic>Signal Transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dunbar, Andrew J.</creatorcontrib><creatorcontrib>Kim, Dongjoo</creatorcontrib><creatorcontrib>Lu, Min</creatorcontrib><creatorcontrib>Farina, Mirko</creatorcontrib><creatorcontrib>Bowman, Robert L.</creatorcontrib><creatorcontrib>Yang, Julie L.</creatorcontrib><creatorcontrib>Park, Young</creatorcontrib><creatorcontrib>Karzai, Abdul</creatorcontrib><creatorcontrib>Xiao, Wenbin</creatorcontrib><creatorcontrib>Zaroogian, Zach</creatorcontrib><creatorcontrib>O’Connor, Kavi</creatorcontrib><creatorcontrib>Mowla, Shoron</creatorcontrib><creatorcontrib>Gobbo, Francesca</creatorcontrib><creatorcontrib>Verachi, Paola</creatorcontrib><creatorcontrib>Martelli, Fabrizio</creatorcontrib><creatorcontrib>Sarli, Giuseppe</creatorcontrib><creatorcontrib>Xia, Lijuan</creatorcontrib><creatorcontrib>Elmansy, Nada</creatorcontrib><creatorcontrib>Kleppe, Maria</creatorcontrib><creatorcontrib>Chen, Zhuo</creatorcontrib><creatorcontrib>Xiao, Yang</creatorcontrib><creatorcontrib>McGovern, Erin</creatorcontrib><creatorcontrib>Snyder, Jenna</creatorcontrib><creatorcontrib>Krishnan, Aishwarya</creatorcontrib><creatorcontrib>Hill, Corrine</creatorcontrib><creatorcontrib>Cordner, Keith</creatorcontrib><creatorcontrib>Zouak, Anouar</creatorcontrib><creatorcontrib>Salama, Mohamed E.</creatorcontrib><creatorcontrib>Yohai, Jayden</creatorcontrib><creatorcontrib>Tucker, Eric</creatorcontrib><creatorcontrib>Chen, Jonathan</creatorcontrib><creatorcontrib>Zhou, Jing</creatorcontrib><creatorcontrib>McConnell, Timothy</creatorcontrib><creatorcontrib>Migliaccio, Anna R.</creatorcontrib><creatorcontrib>Koche, Richard</creatorcontrib><creatorcontrib>Rampal, Raajit</creatorcontrib><creatorcontrib>Fan, Rong</creatorcontrib><creatorcontrib>Levine, Ross L.</creatorcontrib><creatorcontrib>Hoffman, Ronald</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dunbar, Andrew J.</au><au>Kim, Dongjoo</au><au>Lu, Min</au><au>Farina, Mirko</au><au>Bowman, Robert L.</au><au>Yang, Julie L.</au><au>Park, Young</au><au>Karzai, Abdul</au><au>Xiao, Wenbin</au><au>Zaroogian, Zach</au><au>O’Connor, Kavi</au><au>Mowla, Shoron</au><au>Gobbo, Francesca</au><au>Verachi, Paola</au><au>Martelli, Fabrizio</au><au>Sarli, Giuseppe</au><au>Xia, Lijuan</au><au>Elmansy, Nada</au><au>Kleppe, Maria</au><au>Chen, Zhuo</au><au>Xiao, Yang</au><au>McGovern, Erin</au><au>Snyder, Jenna</au><au>Krishnan, Aishwarya</au><au>Hill, Corrine</au><au>Cordner, Keith</au><au>Zouak, Anouar</au><au>Salama, Mohamed E.</au><au>Yohai, Jayden</au><au>Tucker, Eric</au><au>Chen, Jonathan</au><au>Zhou, Jing</au><au>McConnell, Timothy</au><au>Migliaccio, Anna R.</au><au>Koche, Richard</au><au>Rampal, Raajit</au><au>Fan, Rong</au><au>Levine, Ross L.</au><au>Hoffman, Ronald</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2023-05-18</date><risdate>2023</risdate><volume>141</volume><issue>20</issue><spage>2508</spage><epage>2519</epage><pages>2508-2519</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>•MF hematopoietic stem cells aberrantly secrete CXCL8 and exhibit enhanced cell growth/output in response to CXCL8 in vitro.•Genetic deletion or inhibition of Cxcr2 in the hMPLW515L-adoptive transfer model ameliorates fibrosis and improves hematologic parameters. [Display omitted] Proinflammatory signaling is a hallmark feature of human cancer, including in myeloproliferative neoplasms (MPNs), most notably myelofibrosis (MF). Dysregulated inflammatory signaling contributes to fibrotic progression in MF; however, the individual cytokine mediators elicited by malignant MPN cells to promote collagen-producing fibrosis and disease evolution are yet to be fully elucidated. Previously, we identified a critical role for combined constitutive JAK/STAT and aberrant NF-κB proinflammatory signaling in MF development. Using single-cell transcriptional and cytokine-secretion studies of primary cells from patients with MF and the human MPLW515L (hMPLW515L) murine model of MF, we extend our previous work and delineate the role of CXCL8/CXCR2 signaling in MF pathogenesis and bone marrow fibrosis progression. Hematopoietic stem/progenitor cells from patients with MF are enriched for a CXCL8/CXCR2 gene signature and display enhanced proliferation and fitness in response to an exogenous CXCL8 ligand in vitro. Genetic deletion of Cxcr2 in the hMPLW515L-adoptive transfer model abrogates fibrosis and extends overall survival, and pharmacologic inhibition of the CXCR1/2 pathway improves hematologic parameters, attenuates bone marrow fibrosis, and synergizes with JAK inhibitor therapy. Our mechanistic insights provide a rationale for therapeutic targeting of the CXCL8/CXCR2 pathway among patients with MF. Cytokines are known to be proinflammatory messengers in myeloproliferative neoplasms (MPNs) and are suspected to be important in the late stages of these diseases. Using primary human samples, single-cell cytokine profiling, and murine models, Dunbar and colleagues reveal that the CXCL8/CXCR2 cytokine-signaling axis is a key mediator of bone marrow fibrosis in MPN, providing a therapeutically tractable avenue to prevent, or treat, this lethal complication of MPN</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36800567</pmid><doi>10.1182/blood.2022015418</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-2980-9028</orcidid><orcidid>https://orcid.org/0000-0002-8294-8748</orcidid><orcidid>https://orcid.org/0000-0003-4747-6391</orcidid><orcidid>https://orcid.org/0000-0001-7805-8059</orcidid><orcidid>https://orcid.org/0000-0003-3777-5961</orcidid><orcidid>https://orcid.org/0000-0001-8586-8500</orcidid><orcidid>https://orcid.org/0000-0002-7949-0609</orcidid><orcidid>https://orcid.org/0000-0002-5628-5442</orcidid><orcidid>https://orcid.org/0000-0002-7811-242X</orcidid><orcidid>https://orcid.org/0000-0001-7567-0066</orcidid><orcidid>https://orcid.org/0000-0001-6405-3484</orcidid><orcidid>https://orcid.org/0000-0001-7878-4923</orcidid><orcidid>https://orcid.org/0000-0002-4082-4675</orcidid><orcidid>https://orcid.org/0000-0001-6191-5966</orcidid><orcidid>https://orcid.org/0000-0003-1800-271X</orcidid><orcidid>https://orcid.org/0000-0002-8231-8420</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2023-05, Vol.141 (20), p.2508-2519
issn 0006-4971
1528-0020
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10273167
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Animals
Cytokines - metabolism
Humans
Janus Kinase 2 - genetics
Janus Kinase 2 - metabolism
Mice
Myeloid Neoplasia
Myeloproliferative Disorders - genetics
Neoplasms - complications
Primary Myelofibrosis - pathology
Signal Transduction
title CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T21%3A27%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CXCL8/CXCR2%20signaling%20mediates%20bone%20marrow%20fibrosis%20and%20is%20a%20therapeutic%20target%20in%20myelofibrosis&rft.jtitle=Blood&rft.au=Dunbar,%20Andrew%20J.&rft.date=2023-05-18&rft.volume=141&rft.issue=20&rft.spage=2508&rft.epage=2519&rft.pages=2508-2519&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.2022015418&rft_dat=%3Cproquest_pubme%3E2815249369%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2815249369&rft_id=info:pmid/36800567&rft_els_id=S0006497123004329&rfr_iscdi=true